Lawyers defend failure-to-warn suit

Share this article:
Attorneys for a woman who lost an arm to gangrene after an IV administration of Wyeth's anti-nausea drug Phenergan say there is no conflict between a failure-to-warn suit under Vermont law and FDA's regulation of drug labeling. 

In a brief to the US Supreme Court, the attorneys say that unlike the situation with medical devices, in which federal law contains a pre-emption provision, Wyeth is unable to demonstrate a clear congressional intent to have the FDA pre-empt state liability cases. The brief rejects the notion that it would be impossible for drug companies to comply with both state and federal law. “The Federal Food, Drug, and Cosmetics Act does not preclude drug manufacturers from adding or strengthening warnings or instructions regarding their products,” it said.

“Wyeth could have added a stronger warning against IV-push injection at the inception of its FDA approval process or after the drug was approved, through a labeling change.…Wyeth erroneously contends that it would be liable for misbranding or distributing an unauthorized new drug if it complied with the state-law duty to warn of IV-push risks. A drug is not misbranded if it contains true and accurate information about the risks associated with a particular method of administration. There is no credible claim that a court would have rejected a stronger warning or instruction regarding IV-push injection.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...